For Healthcare Professionals

Voclosporin in Adolescents With Lupus Nephritis


About the study

The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescents with active lupus nephritis (LN).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Key Inclusion Criteria:

  1. Previous diagnosis of systemic lupus erythematosus (SLE) as per the 2019 EULAR/ ACR classification criteria.
  2. Subjects with kidney biopsy confirmed active lupus nephritis.


Exclusion Criteria:

Estimated glomerular filtration rate (eGFR) <60 mL/minute/1.73 m2 at screening.

Current or medical history of:

  1. Congenital or acquired immunodeficiency.
  2. Clinically significant drug or alcohol abuse prior to screening.
  3. Malignant neoplasm.
  4. Lymphoproliferative disease or previous total lymphoid irradiation.
  5. Known severe viral infections within 3 months of screening; or known human immunodeficiency virus infection, or hepatitis B or C virus infection at any time prior to screening.
  6. Active tuberculosis (TB) or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.
  7. Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
  8. Other known clinically significant active medical conditions, for which the condition or the treatment of the condition may affect the study assessments or outcomes.

Currently taking or known need for any of the following medications:

Immunosuppression biologic agents within 12 weeks prior to randomization, cyclophosphamide, calcineurin inhibitors (CNIs) and live attenuated vaccines, initiation or dose change of ACE inhibitors/ARBs within 4 weeks prior to randomization, IV corticosteroids and IV immunoglobulin within 2 weeks prior to screening, strong CYP3A4/5 inhibitors and inducers within 2 weeks prior to randomization.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Adolescent Lupus Nephritis

Age (in years)

12 - 17


Phase 3

Participants needed


Est. Completion Date

Jan 31, 2025

Treatment type



Aurinia Pharmaceuticals Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.